Table 1.
Clinical profile of the 21 randomized trials included in the meta-analysis
| Study | Protocola | IPost/control, N/N | Symptom set, hrs | End points |
|---|---|---|---|---|
| Staat et al5 | 60s × 4 | 14/16 | <6 | CK |
| Laskey13 | 90s × 2 | 10/7 | <12 | CK |
| Ma et al14 | 30s × 3 | 47/47 | ≤12 | CK, LVEF |
| Yang et al6 | 30s × 3 | 23/18 | >12 | CK, LVEF, STR |
| Thibault et al7 | 60s × 4 | 17/21 | <6 | LVEF, CK, TN |
| Laskey et al15 | 90s × 2 | 12/12 | ≤6 | CK, LVEF |
| Lønborg et al45 | 30s × 4 | 59/59 | <12 | MISIZE, TN, LVEF, ACE, STR |
| Sörensson et al9 | 60s × 4 | 38/38 | <6 | MISIZE, LVEF, CK |
| Xue et al17 | 60s × 4 | 23/20 | ≤12 | CK, LVEF, STR |
| Lin et al18 | 60s × 3 | 58/63 | LVEF | |
| Garcia et al19 | 30s × 4 | 22/21 | <12 | LVEF, ACE, CK |
| Liu et al20 | 30s × 3 | 30/34 | <12 | CK-MB, LVEF |
| Freixa et al11 | 60s × 4 | 30/31 | <12 | MISIZE, LVEF, CK, CK-MB, TN |
| Zhao et al21 | 60s × 4 | 32/30 | <12 | TN, LVEF |
| Tarantini et al10 | 60s × 4 | 39/39 | <6 | MISIZE, LVEF, TN |
| Thuny et al22 | 60s × 4 | 25/25 | ≤12 | MISIZE, LVEF, CK |
| Elżbieciak et al23 | 60s × 4 | 18/21 | ≤12 | MISIZE, LVEF, ACE |
| Dwyer et al24 | 30s × 4 | 50/52 | ≤6 | MSIZE, LVEF, CK |
| Hahn et al25 | 60s × 4 | 350/350 | <12 | STR, ACE |
| Dong et al26 | 30s × 3 | 32/30 | <12 | TN, LVEF, STR |
| Limalanathan et al12 | 60s × 4 | 136/136 | ≤6 | MISIZE, LVEF, TN, ACE |
Note:
a
Protocol for duration of balloon inflation, in seconds × number of inflations.
Abbreviations: ACE, adverse clinical events; CK, creatine kinase; CK-MB, creatine kinase-MB fraction; IPost, ischemic postconditioning; LVEF, left ventricular ejection fraction; MISIZE, anatomic infarct size estimated by cardiac magnetic resonance imaging; STR, ST-segment resolution; TN, troponin.